Document:

Exhibit 10.18

 

AMENDING
AGREEMENT

 

This Agreement is signed October 12, 2005 but is deemed to confirm
the parties intentions effective as of the 23rd day of November,
2002 (the “Effective Date”).

 

Between:

 

THE UNIVERSITY OF BRITISH COLUMBIA,
a corporation continued under the University Act
of British Columbia and having its administrative offices at 2075 Wesbrook
Mall, Vancouver, British Columbia, V6T 1W5

 

(the “University”)

 

- and -

 

ONCOGENEX TECHNOLOGIES INC.
a corporation incorporated under the laws of Canada, and having offices at Suite 400,
1001 West Broadway, Vancouver, British Columbia, V6H 4B1

 

(the “Licensee”)

 

WHEREAS:

 

A.            The University and the
Licensee entered into a license agreement with a Commencement Date of November 1,
2001 (“BP5 License Agreement”)
pursuant to which the University granted the Licensee an exclusive worldwide
license to the insulin growth factor binding protein – 5 (“BP5”); and

 

B.            The University and the
Licensee entered into a license agreement with a Commencement Date of September 1,
2002 (“Bi-Specific License Agreement”)
pursuant to which the University granted the Licensee an exclusive worldwide
license to three separate technologies: (a) insulin growth factor binding
protein – 2; (b) insulin growth factor binding protein – 2 and insulin
growth factor binding protein – 5; and (c) Relaxin;

 

C.            The Parties agreed
pursuant to Article 11.4 of the Bi-Specific License Agreement that [***].
Further, the Parties agreed in Section 11.4 of the Bi-Specific License
Agreement to amend the BP5 License such that this intent is consistent between
the two Agreements.

 

D.            Pursuant to Section 11.4
of the Bi-Specific License Agreement, the University and the Licensee now wish
to amend the BP5 License Agreement in order that the intent of Section 11.4
of the Bi-Specific License Agreement be carried out.

 

Now therefore, in consideration of the mutual promises and covenants
contained in this Amending Agreement, the parties hereto covenant and agree
with each other as follows:

 

*Certain information in this exhibit has been omitted as confidential,
as indicated by [***]. This information has been filed separately with the
Commission.

 

 

1.             The first paragraph of Article 11.4
of the BP-5 License Agreement (but not subparagraphs 11.4(a), (b), (c) or
(d)) is amended by deleting such first paragraph in its entirety and replacing
it with the following:

 

“The
Parties acknowledge that in addition to the insulin growth
factor binding protein – 5 (“BP5”)
licensed to the Licensee under this Agreement, the Licensee and the University
have entered into a further license agreement for three separate technologies
(the “Bi-Specific License Agreement”):
(a) insulin growth factor binding protein – 2 (“BP2”); (b) insulin growth factor binding protein – 2 and
insulin growth factor binding protein – 5 (“Bi-Specific”); and (c) Relaxin (“Relaxin”). It is intended that one of BP5, BP2 or Bi-Specific
shall become a lead Product of the Licensee, and that the other two
technologies will be used to support the intellectual property position of the
Licensee in respect of such Product. [***]. Therefore, the Licensee shall use
reasonable commercial efforts to develop and exploit the Technology and any
Improvements and to promote, market and sell the Products and utilize the
Technology and any Improvements and to meet or cause to be met the market
demand for the Products and the utilization of the Technology and any
Improvements.

 

[***]

 

Without
limiting the generality of the foregoing, the Licensee shall:”.

 

2.             Schedule “A” of the BP5 License Agreement is amended
by deleting it in its entirety and replacing it with the new Schedule “A” attached hereto.

 

3.             Except as modified
herein, the University and the Licensee confirm that the BP5 License Agreement
remains unmodified and in full force and effect.

 

IN WITNESS WHEREOF the parties have executed this Amendment on June         ,
2005, with the intent of confirming the parties intentions as of the Effective
Date.

 

SIGNED FOR AND ON BEHALF OF

THE UNIVERSITY OF BRITISH COLUMBIA

by its duly authorized officers:

 

	
   

  	
   

  	
  J.P. Heale, PhD, MBA

  
	
   

  	
   

  	
  Associate Director

  
	
  /s/ J.P. Heale

  	
   

  	
  University-Industry Liaison Office

  
	
  Authorized Signatory

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Authorized Signatory 

  	
   

  	
   

  

 

2

 

	
  SIGNED FOR AND ON BEHALF OF 

  	
   

  	
   

  
	
  ONCOGENEX TECHNOLOGIES INC.
  

  	
   

  	
   

  
	
  By its duly authorized officers: 

  	
   

  	
   

  
	
   

  
	
  /s/ Scott Cormack

  	
   

  
	
  Authorized Signatory

  
				

 

3

 

SCHEDULE “A”

 

DESCRIPTION
OF “TECHNOLOGY”

 

The following represents the intellectual property and know-how that is
to be licensed to the Licensee for development of novel treatments of cancer as
contemplated under this License Agreement:

 

	
  UBC

  File #

  	
   

  	
  Inventor(s)

  	
   

  	
  Title

  	
   

  	
  Serial #

  	
   

  	
  Issued Patent #

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  

 

2.             And all applications
that may be filed based on the foregoing, including, without limitation, all
regular, divisional or continuation, in whole or in part, applications based on
the foregoing, and all applications corresponding to the foregoing filed in
countries other than the United States; and

 

3.             Any and all issued
and unexpired re-issues, re-examinations, renewals or extensions that may be
based on any of the patents described above.

 

4Exhibit 10.19

 

SECOND
AMENDING AGREEMENT

 

This Second Amending Agreement is made as of August 30, 2006 (the “Effective Date”).

 

Between:

 

THE UNIVERSITY OF BRITISH COLUMBIA,
a corporation continued under the University Act
of British Columbia and having its Industry Liaison offices at #103 – 6190
Agronomy Road, Vancouver, British Columbia, V6T 1Z3

 

(the “University”)

 

- and -

 

ONCOGENEX TECHNOLOGIES INC.
a corporation incorporated under the laws of Canada, and having offices at Suite 400,
1001 West Broadway, Vancouver, British Columbia, V6H 4B1

 

(the “Licensee”)

 

WHEREAS:

 

A.            The University and the
Licensee entered into a license agreement with a Commencement Date of November 1,
2001 with respect to BP-5 (the “Original BP-5 License Agreement”) pursuant
to which the University granted the Licensee an exclusive worldwide license to
the Technology, as defined in the Original BP-5 License Agreement;

 

B.            The University and the
Licensee entered into a letter agreement dated November 14, 2002 relating
to the Original BP-5 License Agreement (the “Letter
Agreement”);

 

C.            The University and the
Licensee entered into an amending agreement effective as of November 23,
2002 with respect to the Original BP-5 License Agreement (the “Amending Agreement”);

 

D.            The University and the
Licensee now wish to further amend the Original BP-5 License Agreement as set
out below (the Original BP-5 License Agreement as amended by the Amending
Agreement and the Letter Agreement is hereinafter referred to as the “BP-5 License Agreement”).

 

Now therefore, in consideration of the premises and the mutual
covenants contained in this Amending Agreement, and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties hereto covenant and agree with each other as follows:

 

1.             Article 6.6
is hereby amended by adding the following to the end of it:

 

 

“The University consents to the termination
of any shareholders agreements to which the University and the Licensee may be
party, upon the Licensee becoming a reporting issuer under the Securities Act
of British Columbia.”

 

2.             Article 7.1
is hereby deleted and the following substituted therefore:

 

“7.1         The Licensee shall have the right to identify
any process, use or products arising out of the Technology and any University
Improvements that may be patentable and may seek patent protection with respect
thereto, in which case the Licensee shall take all reasonable steps to apply
for a patent in the name of the University provided that the Licensee pays all
costs of applying for, registering and maintaining the patent in those
jurisdictions in which the Licensee might designate that a patent is required. The
choice of patent counsel will be mutually agreed upon between the University
and the Licensee. The University shall remain the client of such patent
counsel, however, the Licensee will provide direct instructions to the patent
counsel on all patent matters relating to the Technology including filing,
prosecution, management, maintenance, including renewals and term extensions
thereof, and the scope and content of patent applications and to request
countries for foreign filings. The Licensee will pay patent counsel for all
costs incurred with respect to any and all patents relating to the Technology. The
Licensee will supply or instruct the patent counsel to supply the University
with copies of all documents and correspondence received and filed in
connection with the prosecution of patents. The Licensee will keep the
University advised as to all material developments with respect to such
applications with sufficient time for
the University to review and respond, and generally not less than 30 days prior
to an applicable patent deadline, unless circumstances reasonably require the
Licensee to act sooner to protect the patents, in which case the Licensee may
act sooner.   The University shall,
as required and at the Licensee’s cost for the University’s reasonable
out-of-pocket expenses, reasonably cooperate with the Licensee, its lawyers and
agents in the filing, prosecution, management and maintenance of the patents.”.

 

3.             The
following is added as Article 10.8:

 

“10.8       Notwithstanding anything contained in this
Article, the parties acknowledge and agree that the Licensee may disclose
Confidential Information to the extent that may be required by applicable
securities laws in connection with the public offering of the Licensee’s
securities and thereafter to comply with its disclosure obligations as a public
company. If required to make such disclosure by any applicable securities laws,
the Licensee shall inform the University in writing by giving notice and will
consider any reasonable comments the University may have. Such notice shall be
generally not less than 48 hours prior to public disclosure unless a delay of
48 hours would violate applicable securities laws, in which case notice shall
be as soon as practicable.”

 

4.             Article 11.1
is hereby deleted and the following substituted therefore:

 

“11.1       Notwithstanding Article 10.7, the Licensee
shall not use any of the UBC Trade-marks or make reference to the University or
its name in any advertising or 

 

2

 

publicity whatsoever, without the prior
written consent of the University, except as required by law. If the Licensee
is required by law to act in contravention of this Article, the Licensee shall
provide the University with sufficient advance notice in writing to permit the
University to bring an application or other proceeding to contest the
requirement.”.

 

5.             Article 11.2
is hereby deleted.

 

6.             Article 11.4
is hereby deleted and the following substituted therefore:

 

“11.4       The Licensee shall use commercially reasonable
efforts to develop and exploit the Technology and any Improvements and to
promote, market and sell the Products and utilize the Technology and any
Improvements and to meet or cause to be met the market demand for the Products
and the utilization of the Technology and any Improvements.”

 

7.             The
contact information for delivery of notices in Article 16.0 is amended as
follows:

 

If to the University:             The Managing Director

University – Industry Liaison Office

University of British Columbia

#103 - 6190 Agronomy Road

Vancouver,
British Columbia

V6T 1Z3

Telephone: (604)
822-8580

Fax:            (604)
822-8589

 

If to the Licensee:                The President

OncoGenex Technologies Inc.

1001 West Broadway, Suite 400

Vancouver, British Columbia

V6H 4B1

Telephone:   (604) 736-3678

Fax:         (604) 736-3687

 

8.             Article 18.3
is hereby amended by adding the following to the end of it as a separate
paragraph:

 

“Notwithstanding anything contained in this Article 18,
the failure to obtain the prior written consent of the University to the events
described in any of Articles 18.3(d), (e) or (f) shall not entitle
the University to terminate this Agreement if at the time of such event the
Licensee is a public company.”

 

9.             Article 18.7
is hereby deleted and the following substituted therefore:

 

“The Licensee shall cease to use the
Technology or any Improvements in any manner whatsoever or to manufacture or
sell the Products within five days from the Effective Date of Termination. The
Licensee shall then deliver or cause to be 

 

3

 

delivered to the University an accounting
within 30 days from the Effective Date of Termination. The accounting will
specify, in or on such terms as the University may in its sole discretion
require, the inventory or stock of Products manufactured and remaining unsold
on the Effective Date of Termination. The University will instruct that the
unsold Products be stored, destroyed or sold under its direction, provided this
Agreement was terminated pursuant to Article 18.2, 18.3 or 18.5. Without
limiting the generality of the foregoing, if this Agreement was terminated
pursuant to Article 18.1, the unsold Products will not be sold by any
party without the prior consent of the University. The Licensee will continue
to make royalty payments to the University in the same manner specified in Article 5
and 6 on all unsold Products that are sold in accordance with this Article 18.7,
notwithstanding anything contained in or any exercise of rights by the
University under Article 18.6 herein.”

 

10.           Except
as modified herein, the University and the Licensee confirm that the BP-5
License Agreement remains unmodified and in full force and effect.

 

11.           The
BP-5 License Agreement as modified by this Agreement constitutes the entire
agreement between the parties relating to the subject matter hereof.

 

This Agreement may be executed by the parties in separate counterparts
and by facsimile, each of which such counterparts when so executed and
delivered shall be deemed to constitute one and the same instrument.

 

IN WITNESS WHEREOF
the parties have executed this Agreement as of the date first above written.

 

	
  SIGNED FOR AND ON BEHALF OF

  
	
  THE UNIVERSITY OF BRITISH COLUMBIA

  
	
  by its duly authorized officers:

  
	
   

  
	
   

  	
   

  	
  J.P. Heale, PhD, MBA

  
	
   

  	
   

  	
  Associate Director

  
	
  /s/ J.P. Heale

  	
   

  	
  University-Industry Liaison

  
	
  Authorized Signatory

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Authorized Signatory

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  SIGNED FOR AND ON BEHALF OF

  	
   

  	
   

  
	
  ONCOGENEX TECHNOLOGIES INC.

  	
   

  	
   

  
	
  By its duly authorized officer:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  /s/ Scott Cormack

  	
   

  	
   

  
	
  Authorized Signatory

  	
   

  	
   

  

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]